This conference provides a forum for institutional investors, research analysts and senior industry executives to discuss investment trends, attend company presentations, conduct one-on-one meetings, and learn about investment opportunities within the biotechnology industry.
BIO launches the first in a series of reports on STEM (science, technology, engineering, and mathematics) education, workforce preparedness strategies, and other innovative programs that that are critical to this nation’s economic leadership.
The U.S. Department of Agriculture announces that it will fully deregulate a variety of biotech alfalfa (so called “Roundup Ready” or “RR” alfalfa, which is genetically engineered to tolerate the herbicide glyophosate).
BIO's commends President Obama for highlighting the need to increase our nation’s global competitiveness and job creation by stimulating investment and research in innovation.
BIO thanks Secretary of Agriculture Tom Vilsack for his leadership on biofuels commercialization and for announcing the funding of new biorefinery projects under the 2008 Farm Bill’s Biorefinery Assistance Program (Section 9003) and funding to recipients in 33 states to support the production and use of advanced biofuels.
BIO applauds Chairman Lucas (R-Okla.) and Ranking Member Peterson (D-Minn.) for convening today’s forum and emphasizing the importance of our science-based regulatory system for agriculture biotechnology.
BIO welcomes the decision by EPA Administrator Lisa Jackson to defer application of CO2 emission permitting to biomass facilities while further studying the lifecycle emissions profile of biogenic carbon.
Hosted by BIO, the exclusive partnering forum brings together U.S. and European drug development companies with Asian biotech and pharmaceutical companies interested in research collaborations and licensing agreements.
The campaign’s goal is to help inform the public about how biotechnology is helping heal, fuel, and feed the world while creating high-wage jobs and driving U.S. leadership in innovation.
BIO releases a report by Health Advances on the limitations of the nation’s reimbursement system for novel diagnostics and the impact of these limitations.
The 2011 BIO International Convention will highlight the latest trends and the newest opportunities for executives, investors, scientists, policy leaders, and media from around the world.